SLC25A6: Potential Drug Target for Neurological Disorders (G293)

Target Name: SLC25A6

NCBI ID: G293

SLC25A6

SLC25A6: Potential Drug Target for Neurological Disorders

SLC25A6 (also known as ANT3Y) is a protein that is expressed in the brain and is known for its role in the development and progression of various neurological disorders, including Alzheimer's disease. The protein is a member of the superfamily of transmembrane protein (SMP), which are a type of gene product that is involved in the formation and function of the cell membrane.

SLC25A6 is a 25-kDa protein that is expressed in the brain and is involved in the development and progression of various neurological disorders, including Alzheimer's disease. The protein is a member of the superfamily of transmembrane protein (SMP), which are a type of gene product that is involved in the formation and function of the cell membrane. It is composed of 254 amino acid residues and has a calculated pI of 12.9.

SLC25A6 is involved in the formation and maintenance of the blood-brain barrier (BBB), which is a specialized barrier that separates the brain from the surrounding blood vessels and is designed to protect the brain from harmful substances that could cause neurological damage. The BBB is made up of tight junctions, which are special types of junctions that form when two cells are joined together, anddesmosomes, which are small vesicles that are attached to the tight junctions. SLC25A6 is thought to be involved in the formation and maintenance of the tight junctions and desmosomes that make up the BBB.

SLC25A6 is also involved in the regulation of the blood-brain barrier. This is done by the protein known asTransmembrane proteases (TMP), which are enzymes that are involved in the breakdown of the BBB. TMP is thought to be involved in the degradation of SLC25A6, which could contribute to the loss of the protein and the development of neurodegeneration.

SLC25A6 is also involved in the regulation of the neurotransmitter serotonin. Serotonin is a neurotransmitter that is involved in mood regulation, appetite, and other physiological processes. SLC25A6 is thought to be involved in the regulation of serotonin levels in the brain, and it is suggested to be a potential drug target for the treatment of mood disorders and other neurological disorders.

In addition to its involvement in the formation and maintenance of the BBB and the regulation of neurotransmitters, SLC25A6 is also thought to be involved in the development and progression of Alzheimer's disease. Studies have shown that SLC25A6 is overexpressed in the brains of individuals with Alzheimer's disease, and that overexpression of the protein has been associated with the development of neurodegeneration in the brain.

Given the involvement of SLC25A6 in the formation and maintenance of the BBB, as well as its involvement in the regulation of neurotransmitters, it is a potential drug target for the treatment of a variety of neurological disorders, including Alzheimer's disease. Studies are currently being conducted to determine the efficacy of SLC25A6 as a drug treatment.

In conclusion, SLC25A6 is a protein that is involved in the formation and maintenance of the blood-brain barrier and is thought to be involved in the development and progression of various neurological disorders, including Alzheimer's disease. Further research is needed to determine the effectiveness of SLC25A6 as a drug treatment.

Protein Name: Solute Carrier Family 25 Member 6

Functions: ADP:ATP antiporter that mediates import of ADP into the mitochondrial matrix for ATP synthesis, and export of ATP out to fuel the cell (By similarity). Cycles between the cytoplasmic-open state (c-state) and the matrix-open state (m-state): operates by the alternating access mechanism with a single substrate-binding site intermittently exposed to either the cytosolic (c-state) or matrix (m-state) side of the inner mitochondrial membrane (By similarity). In addition to its ADP:ATP antiporter activity, also involved in mitochondrial uncoupling and mitochondrial permeability transition pore (mPTP) activity (PubMed:15033708). Plays a role in mitochondrial uncoupling by acting as a proton transporter: proton transport uncouples the proton flows via the electron transport chain and ATP synthase to reduce the efficiency of ATP production and cause mitochondrial thermogenesis (By similarity). Proton transporter activity is inhibited by ADP:ATP antiporter activity, suggesting that SLC25A6/ANT3 acts as a master regulator of mitochondrial energy output by maintaining a delicate balance between ATP production (ADP:ATP antiporter activity) and thermogenesis (proton transporter activity) (By similarity). Proton transporter activity requires free fatty acids as cofactor, but does not transport it (By similarity). Also plays a key role in mPTP opening, a non-specific pore that enables free passage of the mitochondrial membranes to solutes of up to 1.5 kDa, and which contributes to cell death (PubMed:15033708). It is however unclear if SLC25A6/ANT3 constitutes a pore-forming component of mPTP or regulates it (By similarity)

The "SLC25A6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC25A6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets